For the 200-mg dose (in either form) or the 100-mg syringe, remove it from the refrigerator at least 30 minutes before your injection. After you bring a dose of Dupixent to room temperature ...

Dupixent (dupilumab) is a prescription drug that’s used to treat certain inflammatory conditions, such as atopic dermatitis (a type of eczema). Dupixent comes in a prefilled syringe or prefilled ...

FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade TARRYTOWN, N.Y. and PARIS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Regeneron ...

Dupixent (dupilumab) is a brand-name subcutaneous injection that’s prescribed for certain inflammatory conditions. Dupixent has interactions with some other drugs. Examples include certain ...

What is Dupixent for COPD? Dupixent (dupilumab) is an injectable therapy approved for adults with poorly controlled chronic obstructive pulmonary disease (COPD) and high counts in the bloodstream of a ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

In patients aged one to 11 years with EoE, Dupixent is administered every other week (200 mg for children ≥15 to 30 kg, 300 mg for children ≥30 to 40 kg) or every week (300 mg for children ≥40 kg), ...

(REGN) announced Friday that the U.S. Food and Drug Administration has accepted for review the resubmission of the supplemental biologics license application or sBLA for Dupixent (dupilumab ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic spontaneous urticaria, an inflammatory skin disease. The FDA has accepted the ...

FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade TARRYTOWN, N.Y. and PARIS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Regeneron ...

The BOREAS Phase III trial showed DUPIXENT reduced exacerbations by 30% and improved lung function by 160 mL at 52 weeks. Approximately 44 million COPD cases were recorded in 2023 in the 7MM ...